This is the comparison that matters most, because these two occupy the same niche: a weight-management medicine you swallow. Anyone who has ruled out injections is choosing between them. The answer is less obvious than the coverage of the newer approval implied, and it comes down to trading a genuinely awkward daily routine against a meaningfully better average result.
Two tablets, two entirely different solutions
The Wegovy pill is oral semaglutide, the same active ingredient as the Wegovy injection. Semaglutide is a peptide, essentially a small protein, and digestion destroys proteins. To get a swallowed peptide into the bloodstream at all, the tablet pairs it with an absorption enhancer that helps a fraction of the dose cross the stomach lining. That process is fragile and easily disrupted, which is the source of every restriction attached to it. Orforglipron takes a different route entirely: it is not a peptide but a small molecule, built to fit the same receptor while surviving digestion the way an ordinary tablet does. No enhancer is required, and food in the stomach does not interfere.
The daily routine is where they diverge most
The Wegovy pill has to be taken on waking, on an empty stomach, with no more than about half a glass of plain water, swallowed whole, followed by at least 30 minutes before any food, drink or other medicine. Taken casually with breakfast or coffee, much of the dose is simply lost. Most people adapt within a few weeks and find the routine becomes invisible, but for shift workers, people who take other morning medicines, or anyone whose mornings are chaotic, it is a real and continuing constraint. Orforglipron has none of this. One tablet, any time, with or without food or water. If the routine is what has put you off the existing tablet, this is a genuine solution to it.
The results point the other way
Here the comparison reverses. Oral semaglutide at the weight-management dose produced average weight loss of around 15% of body weight over about 68 weeks in its trial. Orforglipron produced around 11% over 72 weeks in ATTAIN-1. So the tablet with the awkward routine is also the more effective one, by a margin that is not trivial. This is the opposite of what most coverage of the August approval implied, and it is the single most useful thing to know when choosing between them.
Side effects
Broadly similar, because both work through the same receptor. Nausea, constipation, diarrhoea, vomiting and indigestion lead the list for both, concentrated around starting and dose increases and easing as the body adapts. Neither has a clearly gentler profile. One practical difference: because the Wegovy pill must be taken on an empty stomach, people who find nausea worse without food have less room to manoeuvre, whereas orforglipron can be taken with a meal or in the evening, which gives more scope to work around symptoms.
Dose schedules and interactions
Both escalate over months. The Wegovy pill steps up through its own schedule to a weight-management dose considerably higher than the diabetes tablet Rybelsus uses, and orforglipron moves through six doses from 0.8 mg to 17.2 mg with at least 30 days at each. Both slow stomach emptying, so both can affect the absorption of other oral medicines, and both need dose adjustment consideration alongside insulin or a sulfonylurea. The Wegovy pill's 30-minute rule adds a scheduling problem for anyone on other morning medication that orforglipron does not have.
Neither is the diabetes tablet people confuse them with
A recurring source of muddle is Rybelsus, which is also oral semaglutide and also a daily tablet, but is licensed for type 2 diabetes at doses well below the weight-management level. It is not a weight-loss treatment and prescribing it as one is off-label. So there are now three daily tablets in adjacent territory, and they are genuinely different things: Rybelsus for blood sugar at a lower dose, the Wegovy pill for weight management at a higher dose of the same molecule, and orforglipron as a separate molecule authorised for both. Anyone comparing options should be sure which of the three is actually being discussed, because the answers differ substantially.
Availability decides it for now
The Wegovy pill is authorised and available in the UK. Orforglipron was authorised on 10 August 2026 but has not launched, with no confirmed date, so for the present this is a comparison between an option you can actually have and one you cannot. That will change in time, but for now it does mean that anyone weighing them up today is really deciding whether to start treatment now or wait an unknown length of time for a medicine with lower published results.
What each is authorised for
There is a difference here that is easy to miss. Orforglipron carries two authorisations: weight management, and blood sugar control in insufficiently controlled type 2 diabetes. The Wegovy pill is authorised for weight management. If you have type 2 diabetes alongside excess weight, that distinction may shape which conversation a prescriber has with you, and it may mean a different medicine in the same family is the better starting point. The wider point is that the licensed indication, not the marketing category, determines what a prescriber can appropriately offer.
How to choose
If you can live with the morning routine, the evidence favours the Wegovy pill: better average results, available now, and the routine becomes habitual for most people within a month. If the routine is genuinely incompatible with your life, or you have already tried it and could not sustain it, orforglipron will be the better option once it arrives, and a slightly lower average result that you take consistently beats a better one you take badly. Adherence is not a footnote in weight-management treatment; it is most of what determines the outcome.
